Differential immunostaining of various types of breast carcinomas for growth hormone-releasing hormone receptor - Apocrine epithelium and carcinomas emerging as uniformly positive

APMIS

Volumn 122, Issue 9, 2014, Pages 824-831

  Kovári, Bence ^a   Rusz, Orsolya ^a   Schally, Andrew V ^b   Kahán, Zsuzsanna ^a   Cserni, Gábor ^a,c  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c BÁCS KISKUN COUNTY TEACHING HOSPITAL   (Hungary)

Author keywords

Apocrine carcinoma; Breast cancer; Growth hormone releasing hormone receptor; Immunohistochemistry

Indexed keywords

GROWTH HORMONE RELEASING FACTOR RECEPTOR; KI 67 ANTIGEN; POLYCLONAL ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; HORMONE RECEPTOR; MESSENGER RNA; NEUROPEPTIDE RECEPTOR; SOMATOTROPIN RELEASING HORMONE RECEPTOR;

ADULT; AGED; APOCRINE GLAND; ARTICLE; BREAST CALCIFICATION; BREAST CANCER; CANCER GRADING; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAMMOGRAPHY; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST NEOPLASMS; CLASSIFICATION; GENETICS; LUNG CARCINOMA; MAMMARY GLAND; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; RETROSPECTIVE STUDY;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MAMMARY GLANDS, HUMAN; MAMMOGRAPHY; RECEPTOR, ERBB-2; RECEPTORS, NEUROPEPTIDE; RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE; RETROSPECTIVE STUDIES; RNA, MESSENGER;

EID: 84906791981     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12224     Document Type: Article

References (38)

1. Kahán Z, Arencibia JM, Csernus VJ, Groot K, Kineman RD, Robinson WR, et al. Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab 1999;84:582-9.
2. Rekasi Z, Czompoly T, Schally AV, Halmos G. Isolation and sequencing of cDNAs of splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci U S A 2000;97:10561-6.
3. Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 2008;4:33-43.
4. Garcia-Fernandez MO, Schally AV, Varga JL, Groot K, Busto R. The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation. Breast Cancer Res Treat 2003;77:15-26.
5. Chatzistamou I, Schally AV, Kiaris H, Politi E, Varga J, Kanellis G, et al. Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers. Eur J Endocr 2004;151:391-6.
6. Köster F, Engel JB, Schally AV, Hönig A, Schröer A, Seitz S, et al. Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. Breast Cancer Res Treat 2009;116:273-9.
7. Barabutis N, Schally AV. Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines. Br J Cancer 2008;98:1790-6.
8. Barabutis N, Tsellou E, Schally AV, Kouloheri S, Kalofoutis A, Kiaris H. Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor. Proc Natl Acad Sci U S A 2007;104:5575-9.
9. Bellyei S, Schally AV, Zarandi M, Varga JL, Vidaurre I, Pozsgai E. GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. Cancer Lett 2010;293:31-40.
10. Kahán Z, Varga JL, Schally AV, Rekasi Z, Armatis P, Chatzistamou L, et al. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice. Breast Cancer Res Treat 2000;60:71-79.
11. Seitz S, Hohla F, Schally AV, Moder A, Engel JB, Horn F, et al. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist. Oncol Rep 2008;20:1289-94.
12. Havt A, Schally AV, Halmos G, Varga JL, Toller GL, Horvath JE, et al. The expression of the pituitary GHRH receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci U S A 2005;102:17424-9.
13. Gallego R, Pintos E, García-Caballero T, Raghay K, Boulanger L, Beiras A, et al. Cellular distribution of growth hormone-releasing hormone receptor in human reproductive system and breast and prostate cancers. Histol Histopathol 2005;20:697-706.
14. Schulz S, Röcken C, Schulz S. Immunocytochemical localisation of plasma membrane GHRH receptors in human tumours using a novel anti-peptide antibody. Eur J Cancer 2006;42:2390-6.
15. Halmos G, Schally AV, Czompoly T, Krupa M, Varga JL, Rekasi Z. Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. J Clin Endocrinol Metab 2002;87:4707-14.
16. Tabár L, Chen HH, Yen MF, Tot T, Tung TH, Chen LS, et al. Mammographic tumor features can predict long-term outcomes reliably in women with 1-14-mm invasive breast carcinoma. Cancer 2004;101:1745-59.
17. Tabár L, Tot T, Dean PB. Breast Cancer - Early Detection with Mammography. Casting Type Calcifications: Sign of a Subtype with Deceptive Features. Stuttgart: Thieme, 2007.
18. Pálka I, Ormándi K, Gaál S, Boda K, Kahán Z. Casting-type calcifications on the mammogram suggest a higher probability of early relapse and death among high-risk breast cancer patients. Acta Oncol 2007;46:1178-83.
19. Sobin L, Gospodarowicz M, Wittekind Ch, editors. UICC TNM Classification of Malignant Tumours, 7th edn. New York: John Wiley and Sons Inc., 2009.
20. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. New York: Springer, 2009.
21. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, editors. WHO Classification of Tumours of the Breast. International Agency for Research on Cancer: Lyon, 2012.
22. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
23. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-50.
24. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47.
25. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
26. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010;134:e48-72.
27. Product datasheet - Anti-GHRHR antibody ab76263. Available at: http://www.abcam.com/ (accessed 9 June 2013).
28. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72.
29. Tabár L, Chen HH, Duffy SW, Yen MF, Chiang CF, Dean PB, et al. A novel method for prediction of long-term outcome of women with T1a, T1b, and 10-14 mm invasive breast cancers: a prospective study. Lancet 2000;355(9202):429-33.
30. Zunzunegui RG, Chung MA, Oruwari J, Golding D, Marchant DJ, Cady B. Casting-type calcifications with invasion and high-grade ductal carcinoma in situ: a more aggressive disease? Arch Surg 2003;138:537-40.
31. Bennett RL, Evans AJ, Kutt E, Record C, Bobrow LG, Ellis IO, et al. Pathological and mammographic prognostic factors for screen detected cancers in a multi-centre randomised, controlled trial of mammographic screening in women from age 40 to 48 years. Breast 2011;20:525-8.
32. James JJ, Evans AJ, Pinder SE, Macmillan RD, Wilson AR, Ellis IO. Is the presence of mammographic comedo calcification really a prognostic factor for small screen-detected invasive breast cancers? Clin Radiol 2003;58:54-62.
33. Månsson E, Bergkvist L, Christenson G, Persson C, Wärnberg F. Mammographic casting-type calcifications is not a prognostic factor in unifocal small invasive breast cancer: a population-based retrospective cohort study. J Surg Oncol 2009;100:670-4.
34. Seitz S, Rick FG, Schally AV, Treszl A, Hohla F, Szalontay L, et al. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers. Oncol Rep 2013;30:413-8.
35. Tsutsumi Y. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. Jpn J Clin Oncol 2012;42:375-86.
36. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, et al. Identification of molecular apocrine breast tumors by microarray analysis. Oncogene 2005;24:4660-71.
37. Wilkerson PM, Dedes KJ, Lopez-Garcia MA, Reis-Filho JS. The molecular evolution of breast cancer precursors and risk indicators. In: Kahán Z, Tot T, editors. Breast Cancer, a Heterogeneous Disease Entity - The Very Early Stages. Dordrecht-Heidelberg-London-New York: Springer Science+Business Media, 2011: 89-118.
38. Dedes KJ, Wilkerson PM, Reis-Filho JS. Immunohistochemistry and molecular biology of breast cancers: Old and new prognostic factors. In: Kahán Z, Tot T, editors. Breast Cancer, a Heterogeneous Disease Entity - The Very Early Stages. Dordrecht-Heidelberg-London-New York: Springer Science+Business Media, 2011: 119-48.